In addition, chemotoxicity affects tumor growth and attenuates cisplatin chemotherapeutic efficacy by boosting miR-522 release from CAFs through triggering the USP7/hnRNPA1 pathway, whereas preventing miR-522 secretion could inhibit tumor growth and enhance sensitivity to cisplatin (96). The gene discussed is HNRNPA1; the disease is neoplasm.